Actimed Therapeutics Closes £5M Series A Financing

Actimed Therapeutics, a London-based clinical stage specialty pharmaceutical company, has raised £5 million in Series A funding. The round was led by existing investor Mankind Pharma, an India-based pharmaceutical company, and included participation from a number of new non-institutional investors. The company plans to use the funds to support the development of its pipeline, including S-pindolol benzoate, with preparations underway for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.

Actimed Therapeutics Raises £5 Million to Develop Cancer Cachexia Treatment

Actimed Therapeutics is a London, UK-based clinical stage specialty pharmaceutical company focused on the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. The lead area of focus for the company is specifically in cachexia that is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia and it is estimated that cachexia is responsible for up to 20% of all cancer deaths.

Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on the treatment of muscle wasting disorders.

2 years ago

Actimed Therapeutics Raises £5 Million to Develop Cancer Cachexia Treatment

ProblemHealthcare

Solution

Covered on